Medtronic (NYSE:MDT) said today that it launched its Solitaire X revascularization device intended for treating acute ischemic stroke in the U.S.
The Fridley, Minn.-based company’s Solitaire stent retriever uses a micro-sized catheter to access arteries in the brain, restoring blood flow and removing blood clots that cause acute ischemic stroke.
The Solitaire X is the company’s 4th generation device, which features an improved delivery system and the Phenom 21 catheter designed for the delivery of all sizes of the Solitaire X system.
“Medtronic continues to deliver technological innovations to advance stroke treatment. As a long-time Solitaire user, I am impressed with the ease of the Solitaire X delivery. I find that Solitaire X 6×40 device combined with Phenom 21 catheter provides smooth navigation especially when working with complicated anatomy,” Dr. Reza Jahan of UCLA said in a press release.
“Our commitment to enable physicians to improve outcomes for stroke patients worldwide will always be our motivation. The net result of that commitment is the launch of a 4th generation device – Solitaire X – which marks 10 years of innovation in stroke therapy,” neurovascular biz GM Stacey Pugh said in a prepared statement.
Yesterday, Medtronic lost its bid for an appeals court review of its nearly $24 million loss in a patent infringement lawsuit brought by a physician inventor.
